Genentech's immunotherapy improves survival by two months in first-line SCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower133 trial showing that its anti-PD-L1 mAb Tecentriq atezolizumab in combination with chemotherapy led to a two-month overall survival (OS) benefit over chemotherapy alone as first-line treatment of extensive-stage small cell lung cancer.

Genentech reported in June that IMpower133 met its co-primary endpoints of improving OS and progression-free survival (PFS). The company told BioCentury it has submitted the data to FDA and is planning to submit the data to global health authorities...